Li Wei Cho
University of Hull
10 Papers
43 Citations
Li Wei Cho is an academic researcher from University of Hull. The author has contributed to research in topics: Insulin resistance & Polycystic ovary. The author has an hindex of 6, co-authored 10 publications. Previous affiliations of Li Wei Cho include Changi General Hospital.
Chat about Author
Papers
•Journal Article
Cardiometabolic aspects of polycystic ovarian syndrome.
TL;DR: The current evidence for the adverse cardiovascular risk in PCOS and the other factors that may be implicated are addressed and the therapeutic options for treatment will be discussed.
56
A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study
TL;DR: Rimonabant has been found to reduce weight and improve the metabolic profile in patients with obesity, type 2 diabetes and metabolic syndrome.
32
The Biological Variation of C-Reactive Protein in Polycystic Ovarian Syndrome
TL;DR: Whether a PCOS patient’s CRP concentration remains within narrow biological limits or varies more widely over a given time period is established, as well as to correlate its variability to that of insulin resistance.
21
The mean and the biological variation of insulin resistance does not differ between polycystic ovary syndrome and type 2 diabetes.
TL;DR: The progression from PCOS to the development of T2DM is unlikely to be due to a further increase in IR (or variability), but rather the progressive failure of pancreatic beta cells with a decrease in insulin production.
10
Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).
TL;DR: This study was undertaken to determine if subsequent metformin treatment after rimonabant would maintain the improvement in weight, insulin resistance and hyperandrogenaemia in PCOS.
10